Osteocalcin as a treatment for cognitive disorders
View Patent ↗Methods and compositions for treating or preventing cognitive disorders in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, cognitive loss due to neurodegeneration associated with aging, anxiety, depression, memory loss, learning difficulties, and cognitive disorders associated with food deprivation during pregnancy.
1. A method of treating or preventing anxiety, depression, or memory loss in a mammal comprising administering to a mammal in need thereof a pharmaceutical composition comprising a therapeutically effective amount of undercarboxylated/uncarboxylated osteocalcin and a pharmaceutically acceptable carrier or excipient, thereby treating or preventing the anxiety, depression, or memory loss.
2. The method of claim 1 wherein the mammal is a human and the osteocalcin is human osteocalcin.
3. The method of claim 2 wherein the cognitive disorder is anxiety due to aging, depression due to aging, or memory loss due to aging.
4. The method of claim 2 wherein the undercarboxylated/uncarboxylated osteocalcin is a preparation of undercarboxylated/uncarboxylated osteocalcin in which more than about 20% of the total Glu residues at the positions corresponding to positions 17, 21 and 24 of mature human osteocalcin in the preparation are not carboxylated.
5. The method of claim 4 wherein all three of the glutamic acids in the undercarboxylated/uncarboxylated osteocalcin at the positions corresponding to positions 17, 21 and 24 of mature human osteocalcin are not carboxylated.
6. The method of claim 2 wherein the undercarboxylated/uncarboxylated osteocalcin shares at least 80% amino acid sequence identity with mature human osteocalcin when the undercarboxylated/uncarboxylated osteocalcin and mature human osteocalcin are aligned for maximum sequence homology.
7. The method of claim 6 wherein the undercarboxylated/uncarboxylated osteocalcin shares about 98% amino acid sequence identity with mature human osteocalcin when the undercarboxylated/uncarboxylated osteocalcin and mature human osteocalcin are aligned for maximum sequence homology.
8. The method of claim 2 wherein the undercarboxylated/uncarboxylated osteocalcin is a polypeptide selected from the group consisting of:
(a) a fragment comprising mature human osteocalcin missing the last 10 amino acids from the C-terminal end;
(b) a fragment comprising mature human osteocalcin missing the first 10 amino acids from the N-terminal end;
(c) a fragment comprising amino acids 62-90 of SEQ ID NO:2;
(d) a fragment comprising amino acids 1-36 of mature human osteocalcin;
(e) a fragment comprising amino acids 13-26 of mature human osteocalcin; and
(f) a fragment comprising amino acids 13-46 of mature human osteocalcin.
9. The method of claim 2 which is a method of treating or preventing anxiety.
10. The method of claim 2 which is a method of treating or preventing depression.
11. The method of claim 2 which is a method of treating or preventing memory loss.